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Abstract 
Title: Shingles Vaccine: Identifying high risk groups in the IBD clinic setting 
 
Background: The Inflammatory Bowel Disease (IBD) population is an immunocompromised 
patient population who is at risk for Herpes Zoster (HZ) due to their medication regimen, which 
further compromises their immune system. It can be difficult for patients to receive appropriate 
preventative health maintenance measures due to patients’ fears, primary care providers’ lack of 
knowledge, and gastroenterologists not addressing what may be considered primary care topics. 
Furthermore, evidence demonstrates that IBD patients have low vaccination rates despite 
insurance coverage. 
 
Purpose of Project: (a) To increase awareness of the importance of Shingrix in the Inflammatory 
Bowel Disease population (over 50 years old); (b) To increase Shingrix vaccination orders by 
5% in a two-month period. 
 
EBP Model/Frameworks: The ACE Star model was used to guide this project. 
 
Evidenced-Based Interventions: A PowerPoint presentation will be utilized to educate IBD 
healthcare providers on the newest evidence regarding high risk groups for shingles and 
Shingrix. In addition, posters will be located in every patient room for patient education on 
Shingrix. 
 
Evaluation/Results: No significant difference was found in vaccination rates between pre-and 
post-project implementation of patient posters and staff educational PowerPoint. Limitations 
included small patient sample size in post implementation.    
 
Implication for Practice: Most insurance plans now cover Shingrix for patients aged 50 years 
and older. Spreading awareness of the importance of this vaccination will aid in increasing low 
numbers of vaccination rates in the IBD population.  
 
Conclusion: The new Shingrix vaccine is not a live vaccine, therefore can be administered to 
immunocompromised patients, including those patients who have received the previous shingles 
vaccine, Zostavax. It is essential to assess health maintenance, including vaccines needed, at 
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Shingles Vaccine: Identifying High Risk Groups in the IBD Clinic Setting 
Vaccination rates among the inflammatory bowel disease patient population continue to 
be low despite evidence exposing this population is at an increased risk for contracting illnesses 
due to the disease process and the treatment of immunosuppressive therapies (Gisbert & 
Chapparo, 2013). It Historically, it has been advised to avoid live vaccines in this patient 
population, but now with the newly developed Shingrix vaccine, an attenuated vaccine, this adds 
to the list of recommended vaccines whether on or off immunosuppressive therapy. Another 
issue with the older version of the shingles vaccine, the Zostavax, was that it was recommended 
and covered by most insurances after the age of 60; this new vaccine, Shingrix, is recommended 
and covered by most insurances for patients over the age of 50. Regardless of whether the patient 
has received the Zostavax in the past, the Shingrix is recommended. 
Background and Significance 
 The Inflammatory Bowel Disease (IBD) population is an immunocompromised patient 
population who is at further risk for Herpes Zoster (HZ) due to their treatment regimen. In a 
review article of previous research, it is hypothesized that the features of IBD, in combination 
with immunosuppressive therapy, could result in lower response rates of vaccinations, thus 
making it imperative to give vaccinations before implementing therapy if possible (Gisbert & 
Chaparro, 2013). Patients at highest risk for acquiring Herpes Zoster include those on triple 
immunosuppressive therapy including corticosteroids, disease-modifying antirheumatic drugs 
(DMARDs), and biologics. Studies show it can be difficult for patients to receive appropriate 
preventative health maintenance measures due to patients’ fears, primary care providers’ lack of 
knowledge, and gastroenterologists not addressing primary care topics (Reich, Wasan, & 
Farraye, 2016). Ways to close these gaps in care would be to assess health maintenance at an 
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initial gastroenterologist visit and send primary care provider recommendations for vaccine 
administration. Furthermore, evidence demonstrates that IBD patients have low vaccination rates 
despite insurance coverage (Reich et al., 2016). 
Purpose of Project 
 The purpose of this evidence-based project was to increase awareness of the importance 
of the Shingrix vaccine in the inflammatory bowel disease population, over the age of 50. The 
goal was to increase vaccination orders and recommendation rates for this high-risk group by 5% 
in a 2-month period. A PowerPoint presentation was utilized to educate IBD healthcare providers 
on the crucial information and literature findings. In addition, posters, which included side 
effects of the vaccine and pricing information, were located in every patient room for patient 
education. A chart review was completed on all patients over the age of 50, for the 2 months 
following PowerPoint and poster implementation, to check for number of recommendations and 
orders placed by healthcare providers in this inflammatory bowel disease center in the 
metropolitan area of San Diego, California.  
Literature Review 
While conducting this literature review, the databases Cochrane, CINAHL, and Pub Med 
were used. Key words such as: inflammatory bowel disease, IBD, Crohn’s Disease, Ulcerative 
Colitis, Shingrix, Zostavax, inflammatory bowel disease plus shingles, inflammatory bowel 
disease plus vaccines, and immunosuppressive therapy were searched. As this evidence-based 
project progressed, more articles were found because the Shingrix vaccine has only been 
approved as of October 2017, therefore this topic is slowly surfacing new research findings and 
journal articles.  
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Studies such as one done in Korea (Soh et al., 2019), have looked at the risk of acquiring 
shingles in the inflammatory bowel disease patient population. The retrospective study looked at 
30,100 patients with IBD and matched them by age and gender to 150,500 non-IBD patients. The 
information was gathered between 2010 to 2013 from patients in Korea. The results showed an 
increase risk was evident in patients with inflammatory bowel diseases, especially in those who 
were younger and were otherwise healthy without metabolic comorbidities (Soh et al., 2019).  
In the collection of randomized controlled trial data by Colombel (2018), there was an 
increased risk of HZ for non-TNFi agents overall (abetimus, interleukin-1 receptor antagonist, 
abatacept, tocilizumab, ustekinumab, sifalimumab, and natalizumab data combined) when 
compared to TNFi agents (etanercept, adalimumab, Anbainuo, infliximab, certolizumab pegol, 
and golimumab data combined). Similarly, risks of HZ have been notable for Crohn’s disease 
and ulcerative colitis patients receiving thiopurine therapy (Colombel et al., 2018). Furthermore, 
after biologics such as infliximab, adalimumab, or certolizumab pegol, or combination (both 
thiopurine and biologic) therapies were administered, a slight increase in risk of HZ were 
visualized for patients with ulcerative colitis in comparison to Crohn’s disease. Additionally, in 
the meta-analysis from Colombel (2018), JAK inhibitors, as well as tofacitinib, have been 
associated with HZ risk in patients. It is hypothesized that the key inflammatory cytokines and 
the regulation of the immune response could put the patient at risk for HZ. In this same meta-
analysis, a dose-dependent risk for HZ was observed with tofacitinib, with most cases being non-
complicated, mild to moderate in severity, and manageable with antiviral medication. Therefore, 
tofacitinib can be safely continued after an event of shingles. In fact, most patients in the 
tofacitinib clinical programs were able to continue tofacitinib treatment during their shingles 
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event, with a small portion of patients temporarily discontinuing tofacitinib and resuming after 
antiviral therapy (Colombel, 2018). 
In a meta-analysis inclusive of 57 studies out of 4,225 articles screened, Marra, Lo, 
Kalashnika, and Richardson (2016) looked at the correlation between the risk of HZ and 
immunosuppression therapy. Evidence showed an increased risk of shingles in 
immunocompromised patients taking biologics, particularly non-TNF-α blockers. An increased 
shingles risk was also seen in patients taking corticosteroids and nbDMARDs. Biologics and 
DMARDS are used as treatment for inflammatory bowel disease patients. Biological agents 
differ in their potency when targeting opportunistic infections, and investigating newer agents 
with different therapeutic actions than the traditional TNF-α inhibitors is essential.  
 A higher incidence of HZ cases were detected in patients who were on the medication 
tofacitinib for ulcerative colitis management (Winthrop et al., 2018). The authors observed that 
amongst older individuals, Asian patients, and those with prior TNFi use, who were taking 10mg 
of tofacitinib twice daily, and those with initial corticosteroid use, had higher incidences of HZ 
outbreaks. Age and prior TNFi failure were acknowledged as independent risk factors in 
ulcerative colitis patients who acquired HZ while using tofacitinib. Reports by Winthrop et al. 
(2016) and Winthrop et al. (2018) of patients taking tofacitinib and baricitinib for rheumatoid 
arthritis yielded a 1.5- to 2-fold increase in risk in HZ within some Asian countries compared 
with North American and European regions.  
The higher incidences in Asia for patients taking JAK inhibitors is unknown (Winthrop et 
al., 2018). One possible reason for the increased risk of HZ in rheumatoid arthritis patients taking 
tofacitinib is from a genetic analysis that identified two single nucleotide polymorphisms (SNPs) 
that presented an increased risk within Japanese and Korean populations (Winthrop et al., 2018). 
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The SNPs were intermittently present and were reflected in only a small percentage of the 
increased incidence noted with the patient sample. In this study, there was one case of 
encephalitis and nearly all prior reported cases with tofacitinib, and other JAK inhibitors have 
involved skin or ocular diseases only (Winthrop et al., 2016).  
The mechanism of action by which tofacitinib or other JAK inhibitors increase the risk of 
HZ is unclear. In conclusion, with the data gathered by both Winthrop (2016; 2018) studies, the 
discussion points included the importance of vaccinations for HZ risk management and the 
benefits to all patients with immune-mediated diseases who receive treatment, principally those 
using JAK inhibitors. One recommendation concluded that when HZ occurs, antiviral therapy 
should be considered and tofacitinib temporarily stopped until resolution (Winthrop et al., 2018). 
At the University of Manitoba, an IBD Epidemiology Database was used to identify cases 
of inflammatory bowel disease and controls from 1984 to 2016 who were diagnosed with Herpes 
Zoster before and after 2009, which was when the shingles vaccine was introduced (Nugent, 
Singh, Targownik, & Bernstein, 2018). The university wanted to look at the rates of vaccinations 
for HZ in patients older than age 50. They also investigated if there were any correlations among 
the patients that received the vaccinations. The data demonstrated the control patients were more 
likely to get the HZ vaccine than those with IBD. Patients newly diagnosed with IBD who were 
of higher socioeconomic status also had higher rates of the HZ vaccine. This systematic review 
also noted the incidence of having HZ infections in persons with chronic immune-mediated 
diseases receiving biologics was 60% to 70% more likely than controls (Nugent et al., 2018).  
Studies such as the one by Hechter, Tartof, Jacobsen, Smith, & Tseng (2013) viewed data 
from Kaiser Permanente Southern California and looked at racial disparities and Herpes Zoster 
vaccine rates. The data revealed that within the sample size of 819,466 patients, coverage rate 
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was higher in patients between that ages of 65 and 74 years and who were non-Hispanic White 
females. Coverage among non-Hispanic Whites and Asian/Pacific Islanders was similar and 
higher than the coverage for African-American/African and Hispanics (Hechter et al., 2013). The 
statistics on this study were collected to look at Herpes Zoster vaccination numbers and coverage 
regardless of the presence or absence of disease. These findings, therefore, are not specific to 
IBD, but important to keep in mind, since vaccination rates are already low in the IBD 
population and for African-Americans/Africans and Hispanics. 
In a retrospective study, which included two cohorts of 67,920 participants total, the 
United States Department of Veterans Affairs healthcare system compared the overall risk of 
acquiring Herpes Zoster if patients were taking immunosuppressant therapy (Khan et al., 2018). 
Numbers were collected from patient records between January 1, 2000 and June 30, 2016. The 
results displayed that when compared to patients who did not have IBD, patients with ulcerative 
colitis (UC) and Crohn’s disease (CD) had a significantly higher risk of Herpes Zoster infection. 
Additionally, IBD patients who were treated with 5- aminosalicylate acid (5-ASA) treatment 
alone also had an amplified risk of acquiring herpes zoster. When comparing the patients, who 
were treated with 5-ASA alone, there was also an increased risk for those patients on thiopurines 
or a combination therapy of thiopurines and TNF antagonists. TNF antagonist therapy alone did 
not demonstrate an increased risk of Herpes Zoster (Khan et al., 2018). Even more intriguing, 
this study exposed that vaccination rates nationwide for Herpes Zoster, in the IBD population 
without insurance constraints remained tremendously low. 
Theoretical Model 
For this evidenced-based project, the ACE Star Model of Knowledge Transformation 
(Stevens, 2013) was used to carry out implementation of a quality improvement project that was 
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targeted at increasing Shingrix vaccination rates. There are five points on this model titled: 
discovery research, evidence summary, translation into guidelines, practice integration, and 
process/outcome evaluation. This model was chosen to guide this project due to its simplicity 
and for being applicable to evidence-based practice projects.  
Under the first point, discovery research, a quality improvement project was discussed 
with the facility’s nurse practitioner and medical director. A problem was identified which was 
the low Herpes Zoster vaccination rates in the immunocompromised population. The age range 
of 50 years and older was targeted because the Shingrix vaccine is approved for use in patients 
50 years and older. This was also the step in which databases such as PubMed, CINAHL, and 
Cochrane were used to collect evidence on the importance of the shingles vaccine in the 
inflammatory bowel disease population. 
The second point was the evidence summary, which included a literature review that was 
incorporated into the staff education PowerPoint slide deck. The literature was narrowed down to 
nine articles that included information from medications that caused immunosuppression, to 
pathology of the immunosuppressive disease, low vaccination rates in the IBD population, and 
racial disparities in vaccination numbers of the Herpes Zoster vaccine.  
The third point was translation into guidelines. The Shingrix vaccination guidelines and 
recommendation of the Centers for Disease Control and Prevention (CDC) were used to guide 
the educational portion and recommendations listed in the staff educational PowerPoint. It was 
also recommended that after discussing the vaccine with patients, an order for the vaccine be 
placed or a recommendation note would be written in the patients’ plan-of-care.  
The fourth point was that of practice integration. On December 19, 2018, the project was 
piloted for a total of two months. The posters with vaccine information were placed in patient 
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rooms and the staff education PowerPoint was sent via email for providers to read at their 
convenience in a one week period. Providers were then asked to send an email back stating they 
had reviewed the PowerPoint.  
The final fifth point was the process/outcome evaluation. The project concluded on 
February 19, 2019. Data was collected on pre-and post-PowerPoint and poster implementation. 
The data collected included demographic information as well as pre-and post-orders and 
recommendation numbers of both Shingrix and Zostavax rates.  
Practice Change Process 
 The nurse practitioner at the inflammatory bowel disease center at a large facility in San 
Diego, California was approached by the Doctor of Nursing Practice student regarding the needs 
of the facility. After further discussion, the student and nurse practitioner agreed on a change-of-
practice plan that would be simple enough for providers to incorporate and an educational quality 
improvement project that would bring awareness to the latest research on the shingles vaccine 
which had been approved for patients aged 50 years and older, the year prior on October 2017. 
 Both the student and nurse practitioner presented their proposal to the medical director of 
gastroenterology and he approved both components of the project: emailing an educational 
PowerPoint presentation and posting information flyers in patient rooms to increase awareness of 
the importance of the shingles vaccine, thus encouraging the increase in numbers of Shingrix 
vaccination rates in this vulnerable population. 
 After the PowerPoint slide deck was emailed to staff in the inflammatory bowel disease 
department, data was collected for the two months prior to project implementation and two 
months post- project implementation. Data was collected on patients’ demographics, if they were 
taking immunosuppressive therapy, if they had Zostavax in the past, and if they had any orders 
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or recommendations placed in their charts for the Shingrix vaccine. The quality improvement 
evidence-based project goal was to increase awareness of the importance of Shingrix in the IBD 
population (over 50 years old) and increase vaccination rates for this high-risk group by 5% in a 
two-month period. 
Cost/Benefit Analysis 
 Limited information was available on the cost benefit of the Shingrix vaccine for the 
United States at the time the literature review was completed. This is due to the relatively new 
information that continues to be studied and submitted for publication. One retrospective study 
from Canada showed that in 2011-2012, the average cost of an episode of Herpes Zoster was 
$127.34 (Friesen, Chateau, Falk, Alessi-Severini, & Bugden, 2017). This price included pain 
medications and antivirals. For Herpes Zoster that led to post-herpetic neuralgia, the drug cost 
was approximately $635, including again both antivirals and pain medications; with more 
spending on pain medications due to long term effects. It is estimated that the Shingrix vaccine 
costs approximately $244 per dose in Canada. As future studies and data are collected in the 
United States, there will be better estimates of San Diego prices for episodes of Herpes Zoster, 
episodes leading to post-herpetic neuralgia and, cost benefit analyses specific to medical costs in 
this country. Today in San Diego, the Shingrix vaccine ranges from $150 to $190 per dose 
depending on which pharmacy is used and under which insurance plan. The complete series of 
this vaccine is two doses, therefore this project also emphasized for providers the importance of 
using the vaccine company as a resource for information on reimbursement forms as well as 
GoodRx.com when recommending the vaccine and ordering it for patients.  
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Results 
 The pre-implementation group consisted of 44 patients and the post-implementation 
group consisted of 25 patients. Of the 69 patients in total, 45% were female and 55% were male 
(Figure 1). The patient sample size was further broken down by age groups: 23 patients were in 
their 50s, 30 patients in their 60s, 11 patients in their 70s, and five patients in their 80s (Figure 
2). When looking at how many patients were on immunosuppressive therapy at the time, 11% of 
the pre-implementation group were not on immunosuppressive therapy compared to the post-
implementation group in which 16% of patients were not on immunosuppressive therapy (Figure 
3). The remainder of the sample size was on immunosuppressive therapy, bringing the 
percentages to 88.6% in the pre-implementation group and 84% in the post-implementation 
group. Lastly, the data exposed order and recommendation rates in both the pre-and post-
implementation rates to be 18.9% and 31.6% respectively (Figure 4). The second sample size, 
however, was not large enough to make the difference significant.  
 The patient sample size was acquired by counting all the patients over the age of 50 who 
were seen in the two months before implementing the educational PowerPoint and flyers in the 
patient rooms, and all the patients over 50 years old seen post-project implementation. None of 
the patients in the sample size were seen twice in those two time frames. Data was collected by 
manually reviewing the patients’ charts and analyzing the orders placed, medication orders, 
immunization records, and the clinic visit note recommendations and plan of care. There was no 
significant difference in referral numbers pre-and post-implementation of this evidence-based 
quality improvement project when reviewing chi-square data.  
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Figure 1. Gender of the Sample Size 
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Figure 3. Patients on Immunosuppressive Therapy  
 
 
Figure 4. Number of Shingrix Orders and Recommendations Placed 
 
 
Implications for Practice 
 
 Most insurance plans now cover Shingrix for patients aged 50 years and older. Spreading 
awareness of the importance of vaccination will aid in increasing our low numbers of vaccination 
rates in the IBD population who are especially vulnerable to acquiring the HZ infection. More 
importantly, HZ can be prevented, so it will be imperative to assess health maintenance, which 
includes vaccines needed at initial gastroenterology and primary care visits. As a healthcare 
provider, one can also refer the patient to a pharmacy to receive Shingrix or to their primary care 
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provider and ask that the patient ensure their immunization records are up to date in the 
gastroenterology office. Another recommendation would be to ask patients if they have any 
questions or concerns about the vaccine when recommending it.  
Discussion 
When discussing the results and limitations with the medical director of the facility and 
University of San Diego faculty mentor, all concurred that low vaccination rates for Shingrix in 
the IBD population are a concern. Especially, because patients who had the older live shingles 
vaccine can and should get the newer shingles vaccine because of its higher efficacy rate in 
preventing Herpes Zoster.  
Limitations to reaching the projected goal of significantly increasing Shingrix vaccination 
rates in this vulnerable population were that the provider whose schedule was being monitored 
for data collection changed in the last month, or halfway through project implementation. 
Another possible limitation could have been the providers viewing the PowerPoint on their own 
time instead of scheduling a group in-service meeting for everyone to get the information and 
lecture at the same time. An extension to this project would be to create an alert on the electronic 
medical record system, reminding providers to order the Shingrix vaccine for patients over the 
age of 50 years old. Another suggestion by the medical director of the inflammatory bowel 
disease center was to create a protocol for staff, including nursing staff, to assist with the 
adherence to Shingrix. 
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